We are excited to announce that our chairman, Dr. Ta-Jo Liu, had the privilege of presenting on innovative vaccine delivery using microarray patches (MAPs) at the prestigious TAVI International Conference. This annual event serves as a hub for advancing vaccine innovation in Taiwan through global collaborations. It brought together renowned global and local institutions, including BARDA, PATH, Japan’s SCARDA, Taiwan’s NHRI, and so on, to showcase remarkable solutions for combating current and future outbreaks of enterovirus and influenza.
Dr. Ta-Jo Liu emphasized that microarray patches are poised to revolutionize vaccine delivery, with strong backing from global institutions. He also outlined the roadmap for WCC Biomedical’s vaccine MAP commercialization process, addressing key challenges at each phase. During his speech, Dr. Liu noted, “We are developing mRNA-based vaccine MAPs, which have shown promising progress in preclinical studies. While developing it, we have established automatic mass production facilities capable of producing 10 million microarray patches annually with a high yield rate. We are prepared to scale up production for mRNA vaccine MAPs as soon as we achieve our preclinical objectives.”
At WCC Biomedical, we believe that microarray patches are the key to achieving the world we envision: ‘Cure Without Fear‘